Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. It triggers a short, dose-dependent pulse of growth hormone (GH) through a Gq/phospholipase C/calcium signalling cascade. What sets it apart from older secretagogues such as GHRP-6 and GHRP-2 is selectivity: in the original pharmacology work, it released GH without meaningfully raising ACTH or cortisol. This article explains each step of that mechanism, the pharmacokinetic data behind the pulse, and how ipamorelin compares with its relatives. It is written for researchers and laboratory buyers. Ipamorelin is an investigational compound with no approved medical use, and everything here concerns laboratory research only.

Nextcellpeptides

Explore Ipamorelin Research Material

NextCell Peptides supplies research-grade ipamorelin with clear specifications, professional labeling and COA documentation where applicable.

Visit NextCell Peptides

Key Takeaways

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin/GHS-R1a receptor on pituitary somatotrophs.
Receptor activation signals through Gαq/11, phospholipase C, IP3 and intracellular calcium, which drives exocytosis of stored GH.
In human volunteers the GH pulse peaked at roughly 40 minutes, and the terminal half-life was about 2 hours.
Unlike GHRP-6 and GHRP-2, ipamorelin did not significantly raise ACTH, cortisol or prolactin in the original studies.
It remains an investigational compound: its most advanced clinical programme, in postoperative ileus, did not meet its primary endpoint.

What ipamorelin is
Step one: receptor binding on the somatotroph
Step two: the Gq/PLC/IP3/calcium cascade
Step three: a discrete, pulsatile GH release
Why selectivity is the headline feature
Ipamorelin with a GHRH analogue
What the clinical record shows
Our perspective
Choosing research material for ipamorelin work
FAQ
Sources

What ipamorelin is

Ipamorelin belongs to the growth hormone secretagogue (GHS) class. These are small peptides and peptidomimetics that stimulate GH release by mimicking ghrelin, the endogenous ligand of GHS-R1a. The class traces back to synthetic GH-releasing peptides described in the 1980s. Ipamorelin was the result of a deliberate effort to keep the GH-releasing activity while removing the side activities of earlier members.

The 1998 paper by Raun and colleagues in the European Journal of Endocrinology describes it as a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, showing high GH-releasing potency and efficacy in vitro and in vivo. Its title calls it the first selective growth hormone secretagogue. The unnatural residues (the aminoisobutyric acid at the N-terminus and two D-amino acids) are part of what makes a short peptide a stable, potent receptor ligand.

In a rat pituitary cell assay the reported EC50 for GH release was 1.3 ± 0.4 nmol/L, according to the same paper. That is a measure of potency in a defined in vitro system, not a prediction of behaviour in any other model, so keep that distinction in mind when you design an experiment.

Step one: receptor binding on the somatotroph

The primary target is GHS-R1a, a G-protein-coupled receptor (GPCR) expressed densely on pituitary somatotrophs and also in parts of the hypothalamus. Ipamorelin occupies the same receptor that ghrelin uses. The Raun paper reports that ipamorelin, like GHRP-6, stimulates GH release through a GHRP-like receptor, which is why the whole family is grouped together despite structural differences.

Two points matter for experimental design:

The receptor is shared, the outcome is not. GHRP-6, GHRP-2 and ipamorelin all act at GHS-R1a, yet their downstream endocrine footprints differ. Selectivity is a property of the ligand's effects across the endocrine axis, not of a different receptor.
Ipamorelin is a secretagogue, not GH itself. It prompts the pituitary to release GH it has already synthesised and stored. Its output is therefore limited by the somatotroph's stores and by the somatostatin tone at the time, which is one reason pulses are self-limiting.

Step two: the Gq/PLC/IP3/calcium cascade

Once ipamorelin occupies GHS-R1a, the receptor couples mainly to Gαq/11. A review of the ghrelin receptor system on PubMed Central describes this pathway: activation leads to phospholipase C (PLC) producing inositol trisphosphate (IP3) and diacylglycerol (DAG), and IP3 mobilises intracellular calcium.

The sequence, in order:

Ipamorelin binds GHS-R1a on the somatotroph membrane.
The receptor activates Gαq/11.
Gαq/11 stimulates phospholipase C.
PLC cleaves a membrane phospholipid into IP3 and DAG.
IP3 releases calcium from intracellular stores, and DAG contributes to protein kinase C signalling.
The rise in intracellular calcium drives exocytosis of vesicles containing GH.

The practical consequence is that the readout of the experiment, whether GH in culture medium or in plasma, tracks a calcium-dependent exocytosis event. In cell-based work, the speed of this response is a useful property: it is quick to appear and quick to resolve.

Step three: a discrete, pulsatile GH release

The pharmacokinetic and pharmacodynamic behaviour of ipamorelin is unusually clean for a peptide. A 1999 study in healthy volunteers used a dose-escalation design with intravenous infusion. It reported dose-proportional pharmacokinetics, a terminal half-life of about 2 hours, a clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg.

In the original pharmacology data, the GH pulse after an intravenous dose peaked at about 0.67 hours (roughly 40 minutes) and returned toward baseline within a few hours. For a study designer, this means:

ParameterReported valueWhy it matters in a study designIn vitro potency (rat pituitary EC50)1.3 ± 0.4 nmol/LSets the working concentration range for cell assaysTime of GH peak (human, IV)about 40 minutesDefines the sampling window for pulse captureTerminal half-life (human)about 2 hoursSets the spacing between doses or samplesClearance0.078 L/h/kgNeeded for pharmacokinetic modellingVolume of distribution (steady state)0.22 L/kgIndicates limited distribution beyond extracellular fluid

Because each administration yields one discrete pulse that resolves, ipamorelin works as a pulse generator. It does not produce the sustained elevation that a longer-acting compound or recombinant GH would. Sampling schedules should be built around the early peak: if you only sample at 4 hours, you will miss most of the event.

Why selectivity is the headline feature

The Raun paper reported that ipamorelin stimulated GH in a dose-dependent way without significant increases in ACTH or cortisol, even at doses around 200-fold above the effective dose for GH release. That 200-fold margin is the number most often quoted, and it is the reason ipamorelin is described as selective. The same study states that GHRP-6 and GHRP-2 do raise these hormones.

Ipamorelin vs GHRP-6 vs GHRP-2

FeatureIpamorelinGHRP-6GHRP-2Target receptorGHS-R1aGHS-R1aGHS-R1aStructurePentapeptideHexapeptideHexapeptideGH releaseDose-dependent pulseDose-dependent pulseDose-dependent pulseACTH and cortisolNo significant rise in the original studiesRaisedRaisedAppetite stimulationGenerally described as minimalCommonly reportedReported in some modelsUse in a studyIsolating GH-pulse effectsStudies where broader ghrelin-like activity is of interestStudies needing a strong GH response and accepting wider activity

The ACTH and cortisol row is supported by the 1998 pharmacology paper. The appetite row reflects how these compounds are commonly characterised in the literature rather than a single measured figure, so check the primary papers for the model you use.

The logic for choosing between them is simple. If your question is about the effect of a GH pulse alone, an off-target rise in cortisol is a confounder. Ipamorelin removes most of that noise. If the question concerns ghrelin-like effects more broadly, a less selective compound may be the intended tool. For a deeper side-by-side, see our comparison of ipamorelin and GHRP-6 for laboratory use.

Ipamorelin with a GHRH analogue

In research protocols, ipamorelin is often studied alongside a growth hormone-releasing hormone (GHRH) analogue such as CJC-1295. The mechanistic rationale is that the two act on the same cell through different receptors and second messengers:

GHRH receptor activation works mainly through cAMP and protein kinase A, supporting GH synthesis and release.
GHS-R1a activation works through the PLC and calcium route described above, and is also thought to reduce somatostatin tone, the inhibitory signal on the somatotroph.

With one pathway pressing the accelerator and the other easing the brake, the combined signal is expected to exceed either alone. This is a mechanistic expectation drawn from the signalling biology, and the size of the effect depends on the model, so verify it against primary data for your design rather than assuming a fixed multiplier.

If you are comparing the two compounds as single agents, our article on CJC-1295 versus ipamorelin sets out the differences. For the variant question, CJC-1295 (No DAC) versus CJC-1295 DAC explains why the choice of GHRH analogue changes the pulse profile.

What the clinical record shows

Ipamorelin has no approved medical indication. Its most advanced clinical programme studied postoperative ileus, a stall in bowel function after surgery, on the basis that ghrelin receptor stimulation promotes gut motility. The phase 2 trial reported by Beck and colleagues in 2014 did not meet its primary efficacy endpoint, and development for that indication ended.

Two things can be said fairly about that result. First, it is a statement about postoperative ileus, not about the peptide's mechanism as a selective GH secretagogue, which is well established in the pharmacology literature. Second, the trial is a useful tolerability reference: the compound was reported as well tolerated at 0.03 mg/kg intravenously twice daily in a surgical population. That is not evidence of efficacy, and it is not guidance for any use outside a controlled research setting.

Our perspective

We see the same pattern in many enquiries about ipamorelin: people search for the mechanism, then for a supplier, and the second step is where quality problems start. The mechanism is only informative if the material in the vial is what the label says. A selective, pulsatile profile can be distorted by an under-dosed, degraded or mislabelled batch, and a cortisol response that should not be there can be a sign of the wrong compound rather than a surprising biology result.

For that reason, we treat documentation as part of the product. Batch identification, clear labelling and a certificate of analysis where applicable are what let a researcher connect a result to a specific lot. Our guidance to laboratories is to read the COA against the claimed identity and purity, record the batch number in every protocol, and keep storage conditions consistent across a series of experiments. Our research materials guide for ipamorelin walks through those checks in detail.

We also think the literature should be read plainly. Ipamorelin is a well-characterised research tool with a strong selectivity record, and an investigational compound with a failed clinical trial. Both statements are true, and a responsible researcher holds both.

Choosing research material for ipamorelin work

When you source ipamorelin or a GHRH-analogue combination, the mechanism tells you what to look for in the documentation:

Identity. The sequence and mass should match the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2. Because selectivity depends on the exact structure, an analogue is not a substitute.
Purity. Impurities can carry their own receptor activity. HPLC purity on the COA, tied to the batch number on the vial, is the minimum.
Batch traceability. Pulse-based experiments are sensitive to small differences, so a result should always map to one lot.
Storage and handling. Peptides degrade with heat, moisture and repeated freeze-thaw cycles, so follow the supplier's specification and keep a log.

If your design uses a GHRH analogue together with ipamorelin, we supply a CJC-1295 (No DAC) and ipamorelin combination for laboratory research, and our guide to what research buyers should know about combination products explains how to read their labelling. You can browse the full research peptide catalogue for other compounds. All products are supplied strictly for laboratory research and analytical purposes, and are not intended for human or veterinary use.

FAQ

What is the mechanism of action of ipamorelin?

Ipamorelin binds GHS-R1a, the ghrelin receptor, on pituitary somatotrophs. The receptor signals through Gαq/11 and phospholipase C to produce IP3, which raises intracellular calcium and triggers release of stored growth hormone. The result is a short, dose-dependent GH pulse.

How is ipamorelin different from GHRP-6 and GHRP-2?

All three act on GHS-R1a and release GH. In the original pharmacology work, ipamorelin did so without significantly raising ACTH or cortisol, even at doses about 200 times the effective GH dose, whereas GHRP-6 and GHRP-2 did raise them. That selectivity is why ipamorelin is preferred when a study needs to isolate the effect of a GH pulse.

How long does the ipamorelin GH pulse last?

In a human volunteer study with intravenous infusion, the GH response peaked at roughly 40 minutes and the terminal half-life of ipamorelin was about 2 hours. GH returned toward baseline within a few hours. Sampling plans should therefore capture the first hour in particular.

Are there published studies on ipamorelin?

Yes. The key references are the 1998 pharmacology paper describing its selectivity, the 1999 pharmacokinetic and pharmacodynamic study in healthy volunteers, and the 2014 phase 2 trial in postoperative ileus. The last did not meet its primary endpoint, so ipamorelin remains an investigational compound with no approved medical use.